30.03.2012 - Two European teams have created huge repositories of cancer genomics data that help predict drug response.
Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale sequencing data of 947 of the 1,200 commercially available human cancer cell lines with the pharmacological profiles of 24 anti-cancer drugs. (Nature 29 March) in a „Cancer Cell Line Encyclopaedia (CCLE)". The cell lines reflect the genetic disturbances that drive cancers,“ said Mark Fishman, Chief of the Novartis Institutes for BioMedical Research (NIBR) that led the study. „Probing cell lines with medicines targeted at specific pathways, as done for the CCLE, provides a powerful tool for design of cancer treatment.“ The data, put into the public domain, will help improve developing targeted therapies. The CCLE provides gene expression data, information on copy number changes as well as DNA sequence variations in about 1,600 cancer-related genes. Additionally, algorithms have been developed to predict drug responses based on the cancer cell’s molecular make-up. When a personal genome is matched against these data an optimised therapy can be obtained for this patient.
In a second study, European researchers from the cancer genome project teamed (coordination EBI, Hinxton) up with US doctors from Massachusetts General Hospital to uncover genetic biomarkers of cancer cells’ drug sensitivity against 130 compounds under clinical and preclinical development (Nature 29.3.). The study was carried out analysing 630 human tumour cell lines representing cancers of epthelial, mesenchymal and hematopoetic origin. The identified cancer subtypes and drug response profiles have been put to the public domain to help researchers engaged in the development of personalised cancer treatments.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.